These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34017343)

  • 1. Antibodies Elicited by the
    Micoli F; Rossi O; Conti V; Launay O; Sciré AS; Aruta MG; Nakakana UN; Marchetti E; Rappuoli R; Saul A; Martin LB; Necchi F; Podda A
    Front Immunol; 2021; 12():671325. PubMed ID: 34017343
    [No Abstract]   [Full Text] [Related]  

  • 2. Complement-mediated serum bactericidal activity of antibodies elicited by the
    Kapulu MC; Nakakana U; Sciré AS; Sarakinou E; Conti V; Rossi O; Acquaviva A; Necchi F; Obiero CW; Martin LB; Bejon P; Njuguna P; Micoli F; Podda A
    Front Immunol; 2022; 13():971866. PubMed ID: 36203568
    [No Abstract]   [Full Text] [Related]  

  • 3. Booster Vaccination With GVGH
    Launay O; Ndiaye AGW; Conti V; Loulergue P; Sciré AS; Landre AM; Ferruzzi P; Nedjaai N; Schütte LD; Auerbach J; Marchetti E; Saul A; Martin LB; Podda A
    Front Immunol; 2019; 10():335. PubMed ID: 30906291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.
    Launay O; Lewis DJM; Anemona A; Loulergue P; Leahy J; Sciré AS; Maugard A; Marchetti E; Zancan S; Huo Z; Rondini S; Marhaba R; Finco O; Martin LB; Auerbach J; Cohen D; Saul A; Gerke C; Podda A
    EBioMedicine; 2017 Aug; 22():164-172. PubMed ID: 28735965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of FAcE (Formulated Alhydrogel competitive ELISA) method for direct quantification of OAg present in Shigella sonnei GMMA-based vaccine and its optimization using Design of Experiments approach.
    Necchi F; Carducci M; Pisoni I; Rossi O; Saul A; Rondini S
    J Immunol Methods; 2019 Aug; 471():11-17. PubMed ID: 31039338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting the contribution of O-Antigen and proteins to the immunogenicity of Shigella sonnei generalized modules for membrane antigens (GMMA).
    Mancini F; Gasperini G; Rossi O; Aruta MG; Raso MM; Alfini R; Biagini M; Necchi F; Micoli F
    Sci Rep; 2021 Jan; 11(1):906. PubMed ID: 33441861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB.
    Gerke C; Colucci AM; Giannelli C; Sanzone S; Vitali CG; Sollai L; Rossi O; Martin LB; Auerbach J; Di Cioccio V; Saul A
    PLoS One; 2015; 10(8):e0134478. PubMed ID: 26248044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
    Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
    [No Abstract]   [Full Text] [Related]  

  • 9. A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against
    Obiero CW; Ndiaye AGW; Sciré AS; Kaunyangi BM; Marchetti E; Gone AM; Schütte LD; Riccucci D; Auerbach J; Saul A; Martin LB; Bejon P; Njuguna P; Podda A
    Front Immunol; 2017; 8():1884. PubMed ID: 29375556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the Role of GMMA Components in the Immunogenicity of a 4-Valent Vaccine against
    Mancini F; Alfini R; Caradonna V; Monaci V; Carducci M; Gasperini G; Piccioli D; Biagini M; Giannelli C; Rossi O; Pizza M; Micoli F
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and immunogenicity of the
    Frenck RW; Conti V; Ferruzzi P; Ndiaye AGW; Parker S; McNeal MM; Dickey M; Granada JP; Cilio GL; De Ryck I; Necchi F; Suvarnapunya AE; Rossi O; Acquaviva A; Chandrasekaran L; Clarkson KA; Auerbach J; Marchetti E; Kaminski RW; Micoli F; Rappuoli R; Saul A; Martin LB; Podda A
    EClinicalMedicine; 2021 Sep; 39():101076. PubMed ID: 34430837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
    Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
    Clarkson KA; Frenck RW; Dickey M; Suvarnapunya AE; Chandrasekaran L; Weerts HP; Heaney CD; McNeal M; Detizio K; Parker S; Hoeper A; Bourgeois AL; Porter CK; Venkatesan MM; Kaminski RW
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32968012
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
    Riddle MS; Kaminski RW; Di Paolo C; Porter CK; Gutierrez RL; Clarkson KA; Weerts HE; Duplessis C; Castellano A; Alaimo C; Paolino K; Gormley R; Gambillara Fonck V
    Clin Vaccine Immunol; 2016 Dec; 23(12):908-917. PubMed ID: 27581434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on Neutropenia.
    De Ryck I; Sarakinou E; Nakakana U; Cilio GL; Ndiaye A; Vella V; Auerbach J; Granada JP; Conti V; Podda A
    Infect Dis Ther; 2022 Apr; 11(2):757-770. PubMed ID: 35118580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of WRSS1, a
    Raqib R; Sarker P; Zaman K; Alam NH; Wierzba TF; Maier N; Talukder K; Baqui AH; Suvarnapunya AE; Qadri F; Walker RI; Fix A; Venkatesan MM
    Hum Vaccin Immunother; 2019; 15(6):1326-1337. PubMed ID: 30794051
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.
    Cohen D; Ashkenazi S; Schneerson R; Farzam N; Bialik A; Meron-Sudai S; Asato V; Goren S; Baran TZ; Muhsen K; Gilbert PB; MacLennan CA
    Clin Microbiol Infect; 2023 Mar; 29(3):366-371. PubMed ID: 36243351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes.
    Citiulo F; Necchi F; Mancini F; Rossi O; Aruta MG; Gasperini G; Alfini R; Rondini S; Micoli F; Rappuoli R; Saul A; Martin LB
    PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009826. PubMed ID: 34644291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.